A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

By
September 24, 2026
11 min

Baptist Health South Florida

1

The FDA has approved daraxonrasib, a targeted therapy for adults with metastatic pancreatic adenocarcinoma, developed with Baptist Health's research.
2

Daraxonrasib targets activated KRAS proteins, differing from traditional chemotherapy by directly cutting off cancer cell growth signals.
3

In the RASolute 302 Phase 3 trial, patients on daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months with chemotherapy.
4

Common side effects of daraxonrasib include rash, diarrhea, and nausea, but most are manageable with dose adjustments and supportive care.
5

The approval of daraxonrasib may signal a shift away from chemotherapy in pancreatic cancer treatment, focusing on personalized therapies.

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

1

2

3

4

5

Original Source(s)

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Related Content

AI-Designed Binder Improves CAR T Cell Activity in Mice

Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027